RapidAI has announced the receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for the latest version of its Rapid ICH product, an artificial intelligence (AI)-powered tool designed to assist in the triage and notification of suspected intracranial hemorrhage (ICH) in non-contrast head CT images. This updated version boasts a 97% sensitivity and 100% specificity, making it one of the most accurate solutions available for ICH detection. By analyzing CT scans, Rapid ICH can detect hemorrhages as small as 0.4 ml, prioritize cases within the radiology worklist, and automatically send notifications to PACS, email, and the Rapid mobile app, thereby streamlining decision-making processes for clinicians. The integration of Rapid ICH with Rapid Hyperdensity further enhances its capabilities by quantifying and characterizing hyperdense regions, providing additional context to aid in triage and transfer decisions. This advancement aims to reduce false positives and alleviate notification fatigue among healthcare providers, ultimately improving patient care in acute neurovascular situations